But the year also saw its fair share of restructurings, pipeline culls and clinical trials gone bust. Alzheimer's disease remains as intractable as ever, and concerns linger about development productivity despite the uptick in approvals. Debates over drug pricing, an overhang for the industry for several years, aren't helped by companies pouring investment into replicating similar types of drugs that carry different brand names. Experimentation with AI, though nascent, could in time improve drug discovery and management of clinical trials. Market competition might just lead to downward pressure on pricing in oncology.
Violent games often have a bad reputation with many claiming they fuel aggressive and anti-social behaviour. Now it seems the reality could be even worse with researchers uncovering evidence that games such as Call of Duty affect our brain's ability to process basic human emotions. As a result, chronic violent gameplay could make people'cool, callous and in control' in disturbing situations, researchers warned. Researchers uncovered evidence that games such as Call of Duty (pictured) affect our brain's ability to process basic human emotions. As a result, chronic violent gameplay could make people'cool, callous and in control' Researchers looked at the three games participants played most and noted if they were of a violent nature (such as shooting game Call of Duty) or non-violent (such as Fifa).
Robotics is already changing how we live, shop, invest, travel, and soon, robo-caregivers will transform how we provide care. Advances in AI will deliver extraordinarily innovative services in support of our loved ones. However, the use of robots to care for our children, elderly and disabled will also give rise to some very human questions. Caregiving is social science jargon for providing unpaid support to a family member or friend who has physical, psychological or development needs. Most caregivers do not know what a caregiver is or even know that they are caregivers.
We present a selection of four articles describing deployed applications plus two more articles that discuss work on emerging applications. Since then, we have seen examples of AI applied to domains as varied as medicine, education, manufacturing, transportation, user modeling, and citizen science. The 2014 conference continued the tradition with a selection of 7 deployed applications describing systems in use by their intended end users, and 14 emerging applications describing works in progress. This year's special issue on innovative applications features articles describing four deployed and two emerging applications. The articles include three different types of recommender systems, which may be as much of a critique of the role of technology in society as it is an indication of recent research trends.
At the World Government Summit in Dubai in February, Tesla and SpaceX chief executive Elon Musk said that people would need to become cyborgs to be relevant in an artificial intelligence age. He said that a "merger of biological intelligence and machine intelligence" would be necessary to ensure we stay economically valuable. Soon afterwards, the serial entrepreneur created Neuralink, with the intention of connecting computers directly to human brains. He wants to do this using "neural lace" technology – implanting tiny electrodes into the brain for direct computing capabilities. Brain-computer interfaces (BCI) aren't a new idea.
Scientists could much more precisely test the impact of investigational drugs if we could better identify and group those with similar brain changes and cognitive impairment. To do this, we applied a multilayer clustering algorithm to analyse dozens of data points from a US study called the Alzheimer's Disease Neuroimaging Initiative, including cognition tests, brain scans and spinal fluid biomarkers. The samples were taken from 562 people with mild cognitive impairment followed for up to five years.
The UK-based Biogerontology Research Foundation (BGRF), which seeks to apply scientific knowledge of aging to the diseases and debilities of old age, proudly salutes its director and trustee Alex Zhavoronkov PhD, whose aging and drug discovery company Insilico Medicine has been included in the prestigious AI 100 list for 2018, announced by CB Insights this month. These are a select group of private companies working on groundbreaking artificial intelligence technology. "Last year's AI 100 enjoyed amazing success in the year since earning this recognition. This year's list was culled from 1000 applications and looks even more impressive. These are companies using artificial intelligence in industries from drug discovery and cybersecurity to robotics and legal tech.
Many of these AI-development companies are quickly turning their sights on real-world challenges. Google DeepMind has already moved the AlphaGo Zero system away from the game and onto a comprehensive study of protein folding in the hopes of revealing a treatment for diseases such as Alzheimer's and Parkinson's.
Is artificial intelligence the future of the biotech industry? Players big and small in the pharma industry are beginning to embrace the idea of artificial intelligence. Some innovators, such as Elon Musk, clearly see the use of AI and machine learning as one of the coming cornerstones of the healthcare industry. Earlier this year Musk, the visionary behind companies such as SpaceX and Tesla, launched the biotech company Neuralink, which has the lofty goal of linking the human brain with a computer. Musk has an idea of implanting computers into a human brain as a way to merge man-made software with the power of the brain in order to improve memory or as a way to interface with computers.
The use of diverse types of healthcare information, ranging from medical images to genomic data, is typically a challenge to biomedical research, but a vendor is announcing the development of a platform intended to ease that process. BioSymetrics is setting its sights on facilitating data analytics by launching a platform that prepares diverse types of data for analytical efforts. It's announcing the launch of Augusta, a proprietary technology that enables standardized processing and integration of diverse raw data types, with the intent of facilitating rapid deployment of artificial intelligence projects in precision medicine, health data applications and drug discovery. The platform provides more than 150 modules for the processing of raw MRI, ECG/EEG, EMR, genomic and metabolomics data. The platform grew out of the company's years of work in machine learning, says Gabriel Musso, BioSymetrics' chief scientific officer.